All In Biotech

Drug Trial Radar · NCT05956626

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Aug 25, 2023

Primary completion

Sep 28, 2026

Study completion Sep 28, 2026

Sponsor

Lead sponsor
OcugenIndustry
Sponsor type
Industry
First posted
Jul 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subjects). Phase 1 is complete and closed for enrollment. It was a multicenter, open-label, dose ranging/dose escalation study that enrolled 9 subjects. OCU410ST Phase 1- Retinal Structure and Visual Function Data Results * Safety: Favorable safety and tolerability profile No SAE deemed related to OCU410ST including intraocular inflammation, exudation, endophthalmitis, anterior ischemic optic neuropathy (AIONs) or vasculitis. * Primary Endpoint: Structural Improvement Atrophic lesions grew slower by 48% at 12M in evaluable treated eyes when compared to untreated eyes * Secondary Endpoint: Visual Function (BCVA) 100% evaluable treated eyes demonstrated stabilization or improvement when compared to untreated eyes in visual function OCU410ST Phase 1- Structural and Functional Outcomes at 12M Data Results * The GARDian3 clinical trial for ABCA4- related retinopathies including Stargardt disease builds upon encouraging results and positive data from the Phase 1 GARDian trial, which demonstrated 48% slower lesion growth at 12-month follow-up in evaluable treated eyes compared to untreated eyes * Additionally, evaluable treated eyes showed a statistically significant (p=0.031) and clinically meaningful improvement of nearly 2-line/9-letter gain in best corrected visual acuity (BCVA) at 12-month follow-up when compared to untreated eyes.

Conditions

  • Stargardt Disease

Interventions

  • OCU410STDrug

    Subretinal Administration of OCU410ST

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in atrophic lesion size as measured by Fundus Auto FluorescenceTime frame: 12 months (Screening to 12 months post OCU410ST administration)
  2. Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))Time frame: 12 months (Screening to 12 months post OCU410ST administration)

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona

  • Retinal Consultants Medical Group

    Sacramento, California

  • Vitreo Retinal Associates, P.A.

    Gainesville, Florida

  • Bascom Palmer Eye Institute

    Miami, Florida

  • Advanced Research, LLC

    Pompano Beach, Florida

  • Retina Partners Midwest, P.C.

    Carmel, Indiana

  • Boston Children's Hospital

    Boston, Massachusetts

  • Mississippi Retina Associates

    Jackson, Mississippi

  • The Retina Institute

    St Louis, Missouri

  • Duke Eye Center

    Durham, North Carolina

  • Erie Retina Research, LLC

    Erie, Pennsylvania

  • Retina Consultants of Texas

    Bellaire, Texas

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Valley Retina Institute

    McAllen, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.